Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 37, Issue 3, 1999, Pages 153-158

  Heinrich Nols, J ^a   Schug, B S ^b   Evers, G ^c   Larsimont, V ^d   Elze, M ^e   Blume, H H ^b   Lee, L S ^f   Crawford, F ^f  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b SocraTec R and D   (Germany)

^c ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^d IMFORM GmbH   (Germany)

^e Pharmaceutical Research Associates   (Germany)

^f Ethical Pharmaceuticals Limited   (United Kingdom)

Author keywords

Analgesia; Bioequivalence study; Formulations; Morphine extended release

Indexed keywords

MORPHINE 6 GLUCURONIDE; MORPHINE SULFATE; MST 30; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROCHEMICAL DETECTION; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRURITUS; STEADY STATE; SUSTAINED RELEASE PREPARATION; VERTIGO; VOMITING;

EID: 0033057171     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Blume HH, Schug BS, Potthast H 1996 Influence of food on the bioavailability of controlled/modified release products. In: Kuhlmann J. Weihrauch TR (eds) Clinical Pharmacology 12, Food-Drug Interactions. Zuckschwerdt, München, pp 25-32
2. Brooks I, De Jager R, Blumenreich H, George E, Savarese JJ 1989 Principles of cancer pain management - use of long term oral morphine. J Fam Pract 28: 275-280
3. Brunk SF, Delle M 1974 Morphine metabolism in man. Clin Pharmacol Ther 16: 51-57
4. CPMP Working Party on Efficacy of Medicinal Products 1991 Note for Guidance: Investigation of bioavailability and bioequivalence.
5. Diletti E, Hauschke D, Steinjans VW 1991 Sample size estimation for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 51-58
6. Diletti E, Hauschke D, Steinjans VW 1992 Sample size determination: Extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Int J Clin Pharmacol Ther Toxicol 30: 59-62
7. Drake J, Kirkpatrick CT, Aliyar CA, Crawford FE, Gibson P, Horth CH 1996 Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulation: Oramorph SR and MST Continus. Br J Clin Pharmacol 41: 417-420
8. Gourlay GK, Plummer JL, Cherry DA 1995 Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain 61: 375-381
9. Hanks GW, Hoskin PJ, Aherne GW, Turmer P, Poulain P 1987 Explanation for potency of repeated oral doses of morphine? Lancet 26: 723-724
10. Hasselström J, Säwe J 1993 Morphine pharmacokinetics and metabolism in humans. Clin Pharmacokinet 24: 344-354
11. Hasselström J, Alexander N, Bringel C, Svensson JO, Säwe J 1991 Single dose and steady-state kinetics of morphine and its metabolites in cancer patients - a comparison of two oral formulations. Eur J Clin Pharmacol 40: 585-591
12. Hennksen H, Knudsen J 1986 Controlled evaluation and ongoing clinical experience with sustained release morphine in patients with advanced cancer pain. In: Band P, Stuart J, Towsan T (ed) The International Symposium on Pain Control, pp 69-72
13. Hoskin PJ, Hanks GW, Aherne GW, Chapman D, Littleton P, Filshie J 1989 The bioavailability and pharmacokinetics of morphine after intravenous, oral, and buccal administration in healthy volunteers. Br J Clin Pharmacol 27: 499-505
14. Osborne R, Joel S, Trw D, Slevin M 1988 Analgesic activity of morphine-6-glucuronide. Lancet 1: 828
15. Säwe J, Kager L, Svensson Eng JO, Rane A 1985 Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol 19: 495-501
16. Schuirmann DJ 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm 15: 657-680
17. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittmann KA, Spector S 1992 Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J AOAC Int 75: 19A-26A
18. Twycross RG 1988 Opioid analgesics in cancer pain: current practice and controversies. Cancer Surveys 7: 29-53
19. World Health Organisation 1986 Cancer Pain Relief. WHO, Geneva